ImmunityBio Inc

IBRX

Equity

ISIN US45256X1037 / Valor 110468647

NASDAQ (2024-11-20)

USD 4.88-8.88%

ImmunityBio Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

ImmunityBio Inc is a biotechnology company that focuses on developing comprehensive immunotherapy approaches to target various types of cancer and infectious diseases. The company's platforms aim to activate different components of the immune system, such as natural killer cells, T cells, and macrophages, to establish immune memory and trigger an effective anti-tumor immune response. ImmunityBio is currently conducting clinical trials to assess the safety and efficacy of their therapies and personalized vaccine candidates across multiple tumor types. The company has secured significant funding for commercialization and pipeline expansion efforts, with a focus on potential regulatory approval for their bladder cancer treatment N-803. Additionally, ImmunityBio is collaborating with the National Cancer Institute on a study for Lynch syndrome cancer prevention.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

20.4%1Y

-24.2%3Y

313%5Y

Performance

117%1Y

121%3Y

124%5Y

Volatility